Loose Fibrin Clot Structure and Increased Susceptibility to Lysis Characterize Patients with Central Acute Pulmonary Embolism: The Impact of Isolated EmbolismFunding This work was supported by the Polish National Science Centre (UMO-2015/B/NZ5/02215 to A.U.).
Background Prothrombotic fibrin clot properties are associated with higher early mortality risk in acute pulmonary embolism (PE) patients. It is unknown whether different types of PE are associated with particular clot characteristics.
Methods We assessed 126 normotensive, noncancer acute PE patients (median age: 59 [48–70] years; 52.4% males), who were categorized into central versus peripheral PE with or without concomitant deep vein thrombosis (DVT). Plasma fibrin clot permeability (K s), clot lysis time (CLT), thrombin generation, platelet-derived markers, and fibrinolytic parameters were measured on admission. Plasma fibrin clot morphology was assessed by scanning electron microscopy (SEM).
Results Patients with central PE (n = 76; 60.3%) compared with peripheral PE (n = 50; 39.7%) had 17.8% higher K s and 14.3% shortened CLT (both p < 0.01 after adjustment for potential confounders including fibrinogen), with no differences between segmental and subsegmental PE. SEM analysis demonstrated larger fibrin fiber diameter and pore size in central PE compared with peripheral PE (both p < 0.01). For isolated PE, there was 23.3% higher K s in central PE than in peripheral PE (n = 24; 19%) with no differences in other variables. Central PE combined with DVT (n = 45; 35.7%), as compared with central isolated PE (n = 31; 24.6%), was associated with shortened CLT (all p < 0.05).
Conclusion Our findings suggest that looser fibrin networks composed of thicker fibers with increased susceptibility to lysis characterize patients with central PE, suggesting that fibrin clot phenotype affects the size of thrombi occluding the pulmonary arteries, highlighting the role of fibrin structures in thrombus formation and stability.
Conception and design of the study: A.U.; data collection, analysis, and interpretation: M.Z., J.N., A.J.-S., A.M.-G., M.P., M.J., K.P., G.S., K.M.-S., A.U.; drafting the article or revising it critically for important intellectual content: M.Z., J.N., A.J.-S., A.M.-G., M.P., M.J., K.P., G.S., K.M.-S., A.U.
Eingereicht: 29. Juni 2020
Angenommen: 15. September 2020
13. November 2020 (online)
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Huisman MV, Barco S, Cannegieter SC. et al. Pulmonary embolism. Nat Rev Dis Primers 2018; 4: 18028
- 2 Cohen AT, Agnelli G, Anderson FA. VTE Impact Assessment Group in Europe (VITAE). et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98 (04) 756-764
- 3 Konstantinides SV, Meyer G, Becattini C. The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J 2019; 54 (03) 1901647
- 4 Pena E, Kimpton M, Dennie C, Peterson R, LE Gal G, Carrier M. Difference in interpretation of computed tomography pulmonary angiography diagnosis of subsegmental thrombosis in patients with suspected pulmonary embolism. J Thromb Haemost 2012; 10 (03) 496-498
- 5 Girard P, Sanchez O, Leroyer C. Evaulation du Scanner Spiralé dans l'Embolie Pulmonaire Study Group. et al. Deep venous thrombosis in patients with acute pulmonary embolism: prevalence, risk factors, and clinical significance. Chest 2005; 128 (03) 1593-1600
- 6 Margaglione M, Brancaccio V, De Lucia D. et al. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest 2000; 118 (05) 1405-1411
- 7 Cha SI, Shin KM, Lee JW. et al. Clinical characteristics of patients with peripheral pulmonary embolism. Respiration 2010; 80 (06) 500-508
- 8 Undas A, Natorska J. Improving fibrinolysis in venous thromboembolism: impact of fibrin structure. Expert Rev Hematol 2019; 12 (08) 597-607
- 9 Undas A, Zawilska K, Ciesla-Dul M. et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114 (19) 4272-4278
- 10 Zabczyk M, Plens K, Wojtowicz W, Undas A. Prothrombotic fibrin clot phenotype is associated with recurrent pulmonary embolism after discontinuation of anticoagulant therapy. Arterioscler Thromb Vasc Biol 2017; 37 (02) 365-373
- 11 Cieslik J, Mrozinska S, Broniatowska E, Undas A. Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study. Blood 2018; 131 (07) 797-807
- 12 Undas A. Fibrin clot properties and their modulation in thrombotic disorders. Thromb Haemost 2014; 112 (01) 32-42
- 13 Martinez MR, Cuker A, Mills AM. et al. Enhanced lysis and accelerated establishment of viscoelastic properties of fibrin clots are associated with pulmonary embolism. Am J Physiol Lung Cell Mol Physiol 2014; 306 (05) L397-L404
- 14 Ząbczyk M, Natorska J, Janion-Sadowska A. et al. Prothrombotic fibrin clot properties associated with NETs formation characterize acute pulmonary embolism patients with higher mortality risk. Sci Rep 2020; 10 (01) 11433
- 15 Ząbczyk M, Natorska J, Janion-Sadowska A, Malinowski KP, Janion M, Undas A. Elevated lactate levels in acute pulmonary embolism are associated with prothrombotic fibrin clot properties: contribution of NETs formation. J Clin Med 2020; 9 (04) E953
- 16 Mazur P, Gawęda B, Natorska J. et al. Fibrin structure in organized thrombotic material removed during pulmonary artery endarterectormy: the effect of vessel calibre. J Thromb Thrombolysis 2016; 42 (02) 212-217
- 17 Kupis RW, Goldman-Mazur S, Polak M, Ząbczyk M, Undas A. Faster fibrin clot degradation characterizes patients with central pulmonary embolism at a low risk of recurrent peripheral embolism. Sci Rep 2019; 9 (01) 72
- 18 Baglin T, Gray E, Greaves M. British Committee for Standards in Haematology. et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010; 149 (02) 209-220
- 19 Pieters M, Philippou H, Undas A, de Lange Z, Rijken DC, Mutch NJ. Subcommittee on Factor XIII and Fibrinogen, and the Subcommittee on Fibrinolysis. An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (05) 1007-1012
- 20 Colle JP, Mishal Z, Lesty C. et al. Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications: a possible mechanism for the high thrombotic tendency?. Thromb Haemost 1999; 82 (05) 1482-1489
- 21 Meltzer ME, Lisman T, de Groot PG. et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116 (01) 113-121
- 22 Longstaff C, Kolev K. Basic mechanisms and regulation of fibrinolysis. J Thromb Haemost 2015; 13 (Suppl. 01) S98-S105
- 23 Collet JP, Lesty C, Montalescot G, Weisel JW. Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots. J Biol Chem 2003; 278 (24) 21331-21335
- 24 Undas A, Topór-Madry R, Tracz W. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l. Pol Arch Med Wewn 2009; 119 (06) 354-359
- 25 Pai M, Evans NS, Shah SJ, Green D, Cook D, Crowther MA. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. Thromb Res 2011; 128 (05) 422-430
- 26 Li L, Zhang P, Tian JH, Yang K. Statins for primary prevention of venous thromboembolism. Cochrane Database Syst Rev 2014; , Issue 12. Art. No.: CD008203. DOI: 10.1002/14651858.CD008203.pub3.
- 27 Biere-Rafi S, Hutten BA, Squizzato A. et al. Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J 2013; 34 (24) 1800-1806
- 28 Glynn RJ, Danielson E, Fonseca FA. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360 (18) 1851-1861
- 29 Wu ZY, Li H, Tang YJ. Effect of simvastatin on the SIRT2/NF-κB pathway in rats with acute pulmonary embolism. Pharm Biol 2018; 56 (01) 511-518
- 30 van Langevelde K, Srámek A, Vincken PW, van Rooden JK, Rosendaal FR, Cannegieter SC. Finding the origin of pulmonary emboli with a total-body magnetic resonance direct thrombus imaging technique. Haematologica 2013; 98 (02) 309-315
- 31 Salonen EM, Vartio T, Hedman K, Vaheri A. Binding of fibronectin by the acute phase reactant C-reactive protein. J Biol Chem 1984; 259 (03) 1496-1501
- 32 Kwasny-Krochin B, Gluszko P, Undas A. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis. Thromb Res 2010; 126 (01) e11-e16
- 33 Undas A, Szułdrzynski K, Stepien E. et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2008; 196 (02) 551-557
- 34 Ząbczyk M, Stachowicz A, Natorska J, Olszanecki R, Wiśniewski JR, Undas A. Plasma fibrin clot proteomics in healthy subjects: relation to clot permeability and lysis time. J Proteomics 2019; 208: 103487
- 35 Stępniewski J, Kopeć G, Magoń W, Sobczyk D, Musiałek P, Podolec P. Ultrasound‑assisted, catheter‑directed, low‑dose thrombolysis for the treatment of acute intermediate‑high risk pulmonary embolism. Pol Arch Intern Med 2018; 128 (06) 394-395
- 36 Kopytek M, Zabczyk M, Natorska J. et al. Viscoelastic properties of plasma fibrin clots are similar in patients on rivaroxaban and vitamin K antagonists. J Physiol Pharmacol 2019; 70 (01) 70
- 37 Białas AJ, Kornicki K, Ciebiada M. et al. Monocyte to large platelet ratio as a diagnostic tool for pulmonary embolism in patients with acute exacerbation of chronic obstructive pulmonary disease. Pol Arch Intern Med 2018; 128 (01) 15-23